Sacituzumab Tirumotecan Plus Pembrolizumab Improves Progression-Free Survival in PD-L1–Negative NSCLC

The randomized phase III OptiTROP-Lung06 trial, presented at the ESMO Congress 2026, demonstrated that sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab significantly improved progression-free survival (PFS) in the first-line treatment of PD-L1–negative advanced nonsquamous non-small cell lung cancer (NSCLC). This combination reduced the risk of progression or death by 51% compared to pembrolizumab plus platinum-pemetrexed chemotherapy, with a median PFS of 15.0 months versus 5.7 months, respectively.